Clinical outcomes in patients with early non-small-cell lung cancer treated surgically in Bogota (Colombia)

被引:0
|
作者
Alvarado-Sarzosa, Fernando [1 ]
Martinez-Jaramillo, Stella Isabel [2 ,3 ]
Hellal, Luis Gerardo Garcia-Herreros- [4 ]
Beltran-Jimenez, Rafael Jose [5 ]
Zuluaga-Restrepo, Juan David [6 ]
Parra-Medina, Rafael [7 ]
Escobar-avila, Laura Lucia [8 ]
Toledo-Arenas, Jose Daniel [9 ]
Carvajal-Fierro, Carlos Andres [5 ]
机构
[1] Univ Bosque, Programa Posgrad Cirugia Torax, Inst Nacl Cancerol, Convenio Docencia Serv, Bogota, DC, Colombia
[2] Cirugia Torax, Clin Reina Sofia, Bogota, DC, Colombia
[3] Univ Bosque, Programa Especializac Cirugia Torax, Bogota, DC, Colombia
[4] Fdn Santa Fe Bogota, Cirugia Torax, Bogota, DC, Colombia
[5] Inst Nacl Cancerol, Unidad Func Cirugia Torax, Bogota, DC, Colombia
[6] Clin CES, Cirugia Torax, Medellin, Colombia
[7] Inst Nacl Cancerol, Grp Patol Oncol, Bogota, DC, Colombia
[8] Lab Patol, Clin Reina Sofia, Bogota, DC, Colombia
[9] Univ Bosque, Psiquiatria & Epidemiol, , D C, Bogota, DC, Colombia
来源
REVISTA COLOMBIANA DE CANCEROLOGIA | 2023年 / 27卷 / 02期
关键词
Carcinoma; non-small-cell lung; adenocarcinoma of lung; neoplasm staging; recurrence; VISCERAL PLEURAL INVASION; INTERNATIONAL ASSOCIATION; GRADING SYSTEM; AIR SPACES; CLASSIFICATION; ADENOCARCINOMA; RECURRENCE; EPIDEMIOLOGY; REVISION; PROPOSAL;
D O I
10.35509/01239015.904
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Introduction: In Colombia, information is limited on the survival of patients with lung cancer treated in the early stages. Thus, this study aimed to analyze the clinical outcomes and factors associated with the prognosis of patients with non-small-cell lung cancer (NSCLC) treated surgically in three institutions in Bogota.Methods: Analytical, observational, retrospective, and multicenter study.Results: The study included 101 patients with a median age of 69 years (IQR 63-75); 56 were women (55.4%). Of the patients, 8 (7.9%) had pathological stage 0, 83 (82.2%) were in stage I and 10 (9.9%) in stage II. The 3-year disease-free survival (DFS) of patients with stages 0, I, and II was 100%, 97%, and 58%, respectively. The overall survival (OS) of all included patients at 3 years was 94%. The OS of patients with and without relapse was 78% and 96%. A statistically significant association was found between relapse and stage II (P<0.001), relapse and T3 (P=0.048), relapse and N1 (P<0.001), and relapse and visceral pleura invasion (P=0.002). The only association found with death was relapse (P=0.002).Conclusions: The pathological stage and some special TNM characteristics, such as T3 tumor, the presence of N1 disease, and visceral pleura invasion, were determining factors in DFS. In contrast, the only factor associated with worse OS was relapse.
引用
收藏
页码:240 / 250
页数:11
相关论文
共 50 条
  • [21] Analysis of Early Death in Japanese Patients With Advanced Non-small-cell Lung Cancer Treated With Nivolumab
    Inoue, Takako
    Tamiya, Motohiro
    Tamiya, Akihiro
    Nakahama, Kenji
    Taniguchi, Yoshihiko
    Shiroyama, Takayuki
    Isa, Shin-ichi
    Nishino, Kazumi
    Kumagai, Toru
    Kunimasa, Kei
    Kimura, Madoka
    Suzuki, Hidekazu
    Hirashima, Tomonori
    Atagi, Shinji
    Imamura, Fumio
    CLINICAL LUNG CANCER, 2018, 19 (02) : E171 - E176
  • [22] Practical management of patients with non-small-cell lung cancer treated with gefitinib
    Shah, NT
    Kris, MG
    Pao, W
    Tyson, LB
    Pizzo, BM
    Heinemann, MH
    Ben-Porat, L
    Sachs, DL
    Heelan, RT
    Miller, VA
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (01) : 165 - 174
  • [23] Rare Gene Mutations in Japanese Surgically Resected Non-Small-Cell Lung Cancer Patients
    Nishii, Teppei
    Yokose, Tomoyuki
    Miyagi, Yohei
    Daigo, Yataro
    Matsuzaki, Tomohiko
    Nagata, Masashi
    Isaka, Tetsuya
    Furumoto, Hideyuki
    Ito, Hiroyuki
    Manabe, Saki
    Murakami, Shuji
    Kondo, Tetsuro
    Saito, Haruhiro
    Yamada, Kouzo
    Masuda, Munetaka
    Nakayama, Haruhiko
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S705 - S705
  • [24] Concurrent Chemoradiotherapy for Patients With Postoperative Recurrence of Surgically Resected Non-Small-Cell Lung Cancer
    Takenaka, Tomoyoshi
    Takenoyama, Mitsuhiro
    Toyozawa, Ryo
    Inamasu, Eiko
    Yoshida, Tsukihisa
    Toyokawa, Gouji
    Shiraishi, Yoshimasa
    Hirai, Fumihiko
    Yamaguchi, Masafumi
    Seto, Takashi
    Ichinose, Yukito
    CLINICAL LUNG CANCER, 2015, 16 (01) : 51 - 56
  • [25] Effect of Amrubicin in Patients with Previously Treated Non-Small-Cell Lung Cancer
    Takayama, S.
    Tamura, T.
    Kawajiri, T.
    Nishi, T.
    Kudo, K.
    Kuyama, S.
    Kawakado, K.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S937 - S937
  • [26] Carboplatin and paclitaxel for previously treated patients with non-small-cell lung cancer
    Roa, V
    Conner, A
    Mitchell, RB
    CANCER INVESTIGATION, 1998, 16 (06) : 381 - 384
  • [27] Understanding prognosis and survival outcomes in patients with early-stage non-small-cell lung cancer
    Torrente, Maria
    Sousa, Pedro A.
    Franco, Fabio
    Guerreiro, Gracinda
    Sousa, Alexandre
    Parejo, Consuelo
    Pimentao, Joao
    Provencio, Mariano
    CLINICAL MEDICINE, 2022, 22 : S38 - S40
  • [28] Effect of liver toxicity on clinical outcome of patients with non-small-cell lung cancer treated with pemetrexed
    Sakamori, Yuichi
    Kim, Young Hak
    Yoshida, Hironori
    Nakaoku, Takashi
    Nagai, Hiroki
    Yagi, Yoshitaka
    Ozasa, Hiroaki
    Mishima, Michiaki
    MOLECULAR AND CLINICAL ONCOLOGY, 2015, 3 (02) : 334 - 340
  • [29] Non-small cell lung cancer in surgically treated women
    Rena, Ottavio
    Massera, Fabio
    Boldorini, Renzo
    Papalia, Esther
    Turello, Davide
    Davoli, Fabio
    Baietto, Guido
    Roncon, Alberto
    Robustellini, Mario
    Casadio, Caterina
    TUMORI JOURNAL, 2013, 99 (06): : 661 - 666
  • [30] Clinical trials in non-small-cell lung cancer
    Saxman, SB
    Blatner, GL
    Cheson, BD
    ONCOLOGY-NEW YORK, 1999, 13 (10): : 1384 - +